"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 4 | 0 | 4 |
| 1998 | 4 | 1 | 5 |
| 1999 | 3 | 0 | 3 |
| 2000 | 11 | 0 | 11 |
| 2001 | 9 | 1 | 10 |
| 2002 | 12 | 2 | 14 |
| 2003 | 10 | 3 | 13 |
| 2004 | 12 | 4 | 16 |
| 2005 | 18 | 3 | 21 |
| 2006 | 24 | 1 | 25 |
| 2007 | 25 | 0 | 25 |
| 2008 | 24 | 3 | 27 |
| 2009 | 31 | 10 | 41 |
| 2010 | 35 | 11 | 46 |
| 2011 | 33 | 7 | 40 |
| 2012 | 29 | 8 | 37 |
| 2013 | 22 | 5 | 27 |
| 2014 | 23 | 14 | 37 |
| 2015 | 39 | 5 | 44 |
| 2016 | 22 | 13 | 35 |
| 2017 | 28 | 11 | 39 |
| 2018 | 30 | 9 | 39 |
| 2019 | 27 | 20 | 47 |
| 2020 | 30 | 11 | 41 |
| 2021 | 33 | 6 | 39 |
| 2022 | 25 | 2 | 27 |
| 2023 | 15 | 0 | 15 |
| 2024 | 12 | 9 | 21 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection. Curr Opin HIV AIDS. 2025 May 01; 20(3):249-256.
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
-
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge. Viruses. 2025 Feb 17; 17(2).
-
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. J Virol. 2025 Feb 25; 99(2):e0173024.
-
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
-
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS. 2025 Mar 15; 39(4):448-456.
-
Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis. Front Immunol. 2024; 15:1415475.
-
HIV-1 Elite Controllers Are Characterized by Elevated Levels of CD69-Expressing Natural Killer Cells. J Acquir Immune Defic Syndr. 2024 Dec 15; 97(5):522-532.
-
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial. J Infect. 2024 Dec; 89(6):106285.
-
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).